Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in antihypertensive therapy with a multiple-action drug.

B N Prichard1, B Tomlinson

  • 1Department of Clinical Pharmacology, Rayne Institute, University College and Middlesex School of Medicine, London, United Kingdom.

Drugs
|January 1, 1988
PubMed
Summary

Newer beta-blockers offer improved hypertension treatment by combining beta-receptor blockade with peripheral vasodilation. These multiple-action drugs reduce resistance with less impact on cardiac output.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians.

Hong Kong medical journal = Xianggang yi xue za zhi·2024
Same author

86 Creating homozygous offspring using oviductal sperm deposition with poor quality cryopreserved semen from a transgenic founder goat.

Reproduction, fertility, and development·2022
Same author

Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoin.

Hong Kong medical journal = Xianggang yi xue za zhi·2018
Same author

Nivolumab before and after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2017
Same author

Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.

Journal of clinical pharmacy and therapeutics·2016
Same author

Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.

Bone marrow transplantation·2016

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Beta-blockers are classified by selectivity and intrinsic sympathomimetic activity (ISA).
  • A newer class of beta-blockers exhibits peripheral vasodilator activity alongside beta-receptor blockade.
  • These agents offer distinct hemodynamic profiles compared to traditional beta-blockers.

Purpose of the Study:

  • To review the pharmacological properties of newer beta-blockers with vasodilator activity.
  • To explore the mechanisms responsible for peripheral vasodilation.
  • To assess their relevance in hypertension management.

Main Methods:

  • Classification of beta-blockers based on pharmacological properties.
  • Review of clinical and experimental evidence for newer agents like labetalol, carvedilol, and dilevalol.

Related Experiment Videos

  • Analysis of mechanisms contributing to peripheral vasodilation (alpha-blockade, beta2-agonism, independent actions).

    • Main Results:

    • Newer beta-blockers reduce peripheral resistance and maintain cardiac output.
    • Mechanisms include alpha-receptor blockade (labetalol, carvedilol), beta2-agonism (dilevalol, medroxolol), and independent vasodilation (carvedilol).
    • Evidence from animal studies and human trials supports these vasodilatory actions.

    Conclusions:

    • Beta-blockers with intrinsic vasodilator properties represent a significant advancement in hypertension therapy.
    • Multiple mechanisms contribute to their vasodilatory effects, requiring further investigation.
    • These agents offer improved hemodynamic profiles for managing cardiovascular conditions.